Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,dividendDate,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 29, 2021) 4","Short Ratio (Jul 29, 2021) 4","Short % of Float (Jul 29, 2021) 4","Short % of Shares Outstanding (Jul 29, 2021) 4","Shares Short (prior month Jun 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,HTGM,18440814,6214400,,,-2598692,,-2614952,3903815,-178200,-4082015,-4082015,,-260289,,,,16260,2074204,6156219,2252404,1483323,,-2614952,-2614952,217080903,18879077,18440814,694794,37319891,7435,-198651120,4254904,3596,5743,13576445,7141871,3164413,3596,1367287,35946861,16181828,1421780,7443275,2318130,1682290,-7187054,17391,-7330019,-87737,3675424,-63140,3864058,-8201242,-695,2268,-4548915,280136,-715927,-171732,-100202,-1392608,-142965,28804990,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,6.53,1630526402,-0.26999998,6.75,6.89,6.44,64604,0,"HTG Molecular Diagnostics, Inc.",PRE,us_market,-3.970588,6.44 - 6.89,6.8,0.0,0.0,8,10,finmb_1519732,NasdaqCM,"HTG Molecular Diagnostics, Inc.",USD,94787,75071,3.0300002,0.8657144,3.5 - 7.95,-1.4199996,-0.1786163,1606089600,3.5,7.95,1617638598,1636405200,1636750800,0.089474715,5.321123,1.2088771,0.22718458,-2.2363014,-4.51,-2.92,-2.54,-2.5708663,1.912,5.9937143,0.5362859,40580032,3.4152722,15,America/New_York,EDT,-14400000,False,False,1.44,,,7.95,3.5,5.99,5.32,94.79k,75.07k,6.21M,,5.33M,12.73%,37.10%,293.54k,3.21,4.06%,4.04%,289.82k,,,,,,0.00%,"Nov 22, 2020",,1:15,"Nov 22, 2020","Dec 30, 2020","Jun 29, 2021",-218.12%,-224.66%,-28.84%,-92.47%,7.87M,1.40,5.60%,-1.52M,-16.66M,-17.17M,-4.51,,29.76M,3.04,10.93M,59.27,5.03,1.91,-16.81M,-10.52M,Value,85706,Healthcare,83,"HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",Tucson,877 289 2615,AZ,1609372800,United States,http://www.htgmolecular.com,86400,3430 East Global Loop,520 547 2837,Diagnostics & Research
t-1,HTGM,16840062,6214400,,,-4845858,,-4848307,3859619,-543169,-4402788,-4402788,,-270357,,,,2449,1435146,5837934,1978315,-443070,,-4848307,-4848307,212866206,19787779,16840062,973272,36627841,6283,-196036168,4360787,3741,5853,21777687,8336899,4501741,3741,1473332,35148656,8987844,1250048,7046617,1602874,1352837,-2686169,447666,-2784678,-172004,6527546,-894819,6855524,-620125,-1197,-9732,-4353261,349782,-115584,56997,-154777,527994,-98509,26811757,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,6.53,1630526402,-0.26999998,6.75,6.89,6.44,64604,0,"HTG Molecular Diagnostics, Inc.",PRE,us_market,-3.970588,6.44 - 6.89,6.8,0.0,0.0,8,10,finmb_1519732,NasdaqCM,"HTG Molecular Diagnostics, Inc.",USD,94787,75071,3.0300002,0.8657144,3.5 - 7.95,-1.4199996,-0.1786163,1606089600,3.5,7.95,1617638598,1636405200,1636750800,0.089474715,5.321123,1.2088771,0.22718458,-2.2363014,-4.51,-2.92,-2.54,-2.5708663,1.912,5.9937143,0.5362859,40580032,3.4152722,15,America/New_York,EDT,-14400000,False,False,1.44,,,7.95,3.5,5.99,5.32,94.79k,75.07k,6.21M,,5.33M,12.73%,37.10%,293.54k,3.21,4.06%,4.04%,289.82k,,,,,,0.00%,"Nov 22, 2020",,1:15,"Nov 22, 2020","Dec 30, 2020","Jun 29, 2021",-218.12%,-224.66%,-28.84%,-92.47%,7.87M,1.40,5.60%,-1.52M,-16.66M,-17.17M,-4.51,,29.76M,3.04,10.93M,59.27,5.03,1.91,-16.81M,-10.52M,Value,85706,Healthcare,83,"HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",Tucson,877 289 2615,AZ,1609372800,United States,http://www.htgmolecular.com,86400,3430 East Global Loop,520 547 2837,Diagnostics & Research
t-2,HTGM,14484660,6214400,,,-4288114,,-4289981,4379995,357052,-4022943,-4022943,,-275373,,,,1867,2582998,6605941,2225946,-265171,,-4289981,-4289981,205661999,20713248,14484660,697812,35197908,5224,-191187861,4491773,5298,90356,22397812,7236374,3022139,5298,2236499,32871053,6298075,1588767,8568308,1492126,1348762,5300541,145889,5265701,-254376,1787457,-307000,2450244,3513344,-1225,10326,-3550140,470568,-1222,-218566,-407186,527799,-34840,25634679,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,6.53,1630526402,-0.26999998,6.75,6.89,6.44,64604,0,"HTG Molecular Diagnostics, Inc.",PRE,us_market,-3.970588,6.44 - 6.89,6.8,0.0,0.0,8,10,finmb_1519732,NasdaqCM,"HTG Molecular Diagnostics, Inc.",USD,94787,75071,3.0300002,0.8657144,3.5 - 7.95,-1.4199996,-0.1786163,1606089600,3.5,7.95,1617638598,1636405200,1636750800,0.089474715,5.321123,1.2088771,0.22718458,-2.2363014,-4.51,-2.92,-2.54,-2.5708663,1.912,5.9937143,0.5362859,40580032,3.4152722,15,America/New_York,EDT,-14400000,False,False,1.44,,,7.95,3.5,5.99,5.32,94.79k,75.07k,6.21M,,5.33M,12.73%,37.10%,293.54k,3.21,4.06%,4.04%,289.82k,,,,,,0.00%,"Nov 22, 2020",,1:15,"Nov 22, 2020","Dec 30, 2020","Jun 29, 2021",-218.12%,-224.66%,-28.84%,-92.47%,7.87M,1.40,5.60%,-1.52M,-16.66M,-17.17M,-4.51,,29.76M,3.04,10.93M,59.27,5.03,1.91,-16.81M,-10.52M,Value,85706,Healthcare,83,"HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",Tucson,877 289 2615,AZ,1609372800,United States,http://www.htgmolecular.com,86400,3430 East Global Loop,520 547 2837,Diagnostics & Research
t-3,HTGM,16201354,6214400,,,-5410207,,-5411788,4752321,-419210,-5171531,-5171531,,-273312,,,,1581,1777098,6948629,2196308,-238676,,-5411788,-5411788,203021404,20508751,16201354,994223,36710105,71103,-186897880,4632447,6727,64861,18884468,5986451,1855990,6727,2272883,34372361,11632160,1412201,9446985,1538553,875236,206416,-140386,110076,-253299,2112992,653444,2557012,-2129907,-3664,5478,-4358453,498987,-135143,-358739,-187057,417393,-96340,28385910,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,2,NCM,6.53,1630526402,-0.26999998,6.75,6.89,6.44,64604,0,"HTG Molecular Diagnostics, Inc.",PRE,us_market,-3.970588,6.44 - 6.89,6.8,0.0,0.0,8,10,finmb_1519732,NasdaqCM,"HTG Molecular Diagnostics, Inc.",USD,94787,75071,3.0300002,0.8657144,3.5 - 7.95,-1.4199996,-0.1786163,1606089600,3.5,7.95,1617638598,1636405200,1636750800,0.089474715,5.321123,1.2088771,0.22718458,-2.2363014,-4.51,-2.92,-2.54,-2.5708663,1.912,5.9937143,0.5362859,40580032,3.4152722,15,America/New_York,EDT,-14400000,False,False,1.44,,,7.95,3.5,5.99,5.32,94.79k,75.07k,6.21M,,5.33M,12.73%,37.10%,293.54k,3.21,4.06%,4.04%,289.82k,,,,,,0.00%,"Nov 22, 2020",,1:15,"Nov 22, 2020","Dec 30, 2020","Jun 29, 2021",-218.12%,-224.66%,-28.84%,-92.47%,7.87M,1.40,5.60%,-1.52M,-16.66M,-17.17M,-4.51,,29.76M,3.04,10.93M,59.27,5.03,1.91,-16.81M,-10.52M,Value,85706,Healthcare,83,"HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.",Tucson,877 289 2615,AZ,1609372800,United States,http://www.htgmolecular.com,86400,3430 East Global Loop,520 547 2837,Diagnostics & Research
